Zentalis Pharmaceuticals, Inc.
ZNTLZentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for oncology.
$321.05M+223%
Table of contents
Earnings
Next report
Aug 5, 2026 (In 1 week)EPS estimate-$0.45
Competitors
By market cap
By revenue growth
Profile
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for oncology. The company's primary value proposition centers on its proprietary WEE1 inhibitor, azenosertib, which is designed to target the DNA damage response pathway in patients with ovarian cancer and other solid tumors.
Competitive position
Clinical-stage developer of a potentially first-in-class and best-in-class WEE1 inhibitor targeting specific genetic biomarkers.
GeographiesGlobal, United States
Customer segmentsOncology patients, Clinical trial participants
Business modelR&D intensive, Intellectual property licensing
SuppliersContract manufacturing organizations, Clinical research organizations, Academic research institutions, Raw material suppliers
CustomersSpecialty pharmacies, Hospitals, Oncology clinics
CountryUnited States of America
Listed2020
Employees168.0
CEOJulia Marie Eastland
SectorHealthcare
IndustryBiotechnology
Websitezentalis.com
FilingsSEC EDGAR
Questions, answered.
- What is Zentalis Pharmaceuticals, Inc.'s market cap?
- Zentalis Pharmaceuticals, Inc. (ZNTL) has a market capitalization of $321.1M and trades on NASDAQ.
- Who are Zentalis Pharmaceuticals, Inc.'s competitors?
- Zentalis Pharmaceuticals, Inc.'s key competitors include Pfizer, Arcus Biosciences, Inc., Nuvalent, Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Zentalis Pharmaceuticals, Inc. partner with?
- Zentalis Pharmaceuticals, Inc.'s notable partners include U.S. Food and Drug Administration.
- Where is Zentalis Pharmaceuticals, Inc. headquartered?
- Zentalis Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 168 people. It has been publicly traded since 2020.